National COVID-19 Immunization Program in Mongolia

Dr. Tsolmon Munkhchuluun, MD, MPH
Researcher-National Center for Public Health, Mongolia
Introduction - Mongolia

- 3.3 million people (2m people aged >18)
- 2.13 people per km²
- 1.6 million people in Ulaanbaatar city
- Life expectancy: 70.71 years (2020)
  - Female - 76.22 years
  - Male - 66.71 years
- 2.85 physicians per 1000 people
- Decentralized health system
  - Primary health care
  - Secondary
  - Tertiary
National COVID-19 program-preparedness

• National immunization program database relies on national electronic system of public services (citizen registration, vaccine passport, PCR testing results)
• Immunization sites were based on primary schools in districts in order to decrease workloads in health facilities (during school closure)
• Development of national telecommunication in health care that provides advice for public regarding to the COVID-19 vaccination
• Prioritizing the most high-risk population
• Strategy of allocating different type of vaccines to appropriate population
• Technical guidance on 92 immunization sites and 8 mobile vaccination bus
COVID-19 immunization program timeline

- **22 February 2021.** COVID-19 vaccination program was launched on 22 February when 150,000 doses of AstraZeneca has been delivered to the government of Mongolia through the COVAX.
- The Government of Mongolia received 126000 doses of Pfizer-BioNtech
- Administration of Sputnik –V vaccine has initiated
- Administration of Vero Cell vaccine has been launched

Immunization mass campaign launched in March and April 2021 with theme “For COVID-free summer”
COVID-19 vaccination progress as of 9 June

<table>
<thead>
<tr>
<th>Capacity of vaccines as of 09 June</th>
<th>Vaccination as of 09 June</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AstraZeneca</strong></td>
<td><strong>First dose</strong></td>
</tr>
<tr>
<td>262,800</td>
<td>1,875,003 (90.7%)</td>
</tr>
<tr>
<td><strong>Verocell</strong></td>
<td><strong>Second dose</strong></td>
</tr>
<tr>
<td>4,300,000</td>
<td>1,561,698 (75.5%)</td>
</tr>
<tr>
<td><strong>Sputnik-V</strong></td>
<td><strong>Target population (all</strong></td>
</tr>
<tr>
<td>60,000</td>
<td><strong>citizens aged ≥ 18)</strong></td>
</tr>
<tr>
<td><strong>Pfizer-BioNTech</strong></td>
<td>2,067,292</td>
</tr>
<tr>
<td>126,360</td>
<td></td>
</tr>
<tr>
<td><strong>Total capacity</strong></td>
<td></td>
</tr>
<tr>
<td>4,749,140 (110%)</td>
<td></td>
</tr>
<tr>
<td><strong>Targeted doses</strong></td>
<td></td>
</tr>
<tr>
<td>4,134,584</td>
<td></td>
</tr>
</tbody>
</table>
Daily new cases and vaccination

Share of the population fully vaccinated against COVID-19
Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.
Challenges and Strategies to address vaccine hesitancy

• Vaccine hesitancy towards Vero Cell vaccine due to no approval from WHO for emergency use
• Communication strategy to address misinformation on vaccine’s safety
• Specialist consultations prior to vaccination and monitoring
• Conditional cash transfers to individuals who were fully vaccinated.
Communication strategies on covid-19 vaccines

- Various communication channels (TV, Social Networks, Daily Covid-19 briefs)
- Weekly scientific briefs on covid-19 vaccines by experts
- Constant provision of accurate information to news agencies
- Surveillance on misinformation on vaccines
- Development of national health hotline on covid-19 and vaccines
- Development of common Q&A on official websites of health authorities.
Thank you